Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia

NCT00801489 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT00801489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00801489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
April 4, 2007
Completion date
October 11, 2028
Enrollment
270 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, acute myeloid leukemia with t(8;21); (q22; q22.1); runx1-runx1t1, de novo myelodysplastic syndrome, high risk myelodysplastic syndrome, inv(16), myelodysplastic syndrome with excess blasts, t(16;16), t(8;21), untreated adult acute myeloid leukemia